How to Get Rapamycin (Sirolimus) in Nevada

Nevada Telehealth Laws and Rapamycin Prescribing

Nevada fully permits telehealth prescribing of rapamycin (sirolimus) for both on-label and off-label indications. The state's telehealth statutes (NRS 629.515) allow a physician-patient relationship to be established via synchronous video visit without requiring a prior in-person exam [1].

This matters for rapamycin access because relatively few Nevada-based physicians specialize in prescribing mTOR inhibitors for off-label longevity protocols. Telehealth removes geographic barriers. A patient in Elko or Winnemucca has the same access as someone in Las Vegas or Reno.

Nevada-licensed MDs and DOs can prescribe sirolimus through telehealth after conducting a clinical evaluation and reviewing labs. Nurse practitioners hold full practice authority in Nevada under NRS 632.237, meaning NPs with the appropriate certification can independently prescribe sirolimus without physician oversight [2]. Physician assistants may also prescribe under a collaborative agreement with a supervising physician.

The typical telehealth workflow takes 7 to 14 days from initial consultation to medication in hand. Some platforms offer expedited processing that shortens this to 5 business days. Your provider will order baseline bloodwork, review results, and then transmit the prescription electronically to a pharmacy licensed in Nevada.

What Labs Are Required Before Starting Rapamycin in Nevada

Every prescriber, whether telehealth or in-person, should order baseline labs before initiating sirolimus therapy. This is not optional. Rapamycin affects lipid metabolism, immune function, and glucose homeostasis, and a responsible clinician needs pre-treatment values to monitor for adverse changes [3].

The standard pre-rapamycin lab panel includes:

• Complete blood count (CBC) with differential. Sirolimus can cause dose-dependent thrombocytopenia and leukopenia. The FDA label reports thrombocytopenia in 30% of transplant patients at therapeutic doses [4].
• Comprehensive metabolic panel (CMP). Liver enzymes (AST, ALT) and kidney function (creatinine, eGFR) establish organ function baselines.
• Fasting lipid panel. Hyperlipidemia is the most common metabolic side effect. In the PEARL trial (N=40), rapamycin 5 mg weekly for 8 weeks increased total cholesterol by 11.2% in participants aged 50 to 85 [5].
• Fasting glucose and HbA1c. mTOR inhibition can impair insulin signaling. Monitoring glucose homeostasis is standard practice per the Endocrine Society's recommendations on mTOR inhibitor metabolic effects [6].
• Sirolimus trough level (for transplant dosing only). Off-label weekly dosing protocols generally do not require trough monitoring, though some clinicians order a 24-hour post-dose level after the first month.

Nevada has LabCorp and Quest Diagnostics locations across Las Vegas, Reno, Henderson, Sparks, and Carson City. Most telehealth platforms will send a lab order to the facility nearest you. Results typically return within 48 to 72 hours.

Off-Label Longevity Dosing vs. Transplant Dosing

The dosing gap between these two uses is significant. Transplant patients take 2 mg daily (adjusted to maintain trough levels of 4 to 12 ng/mL), while off-label longevity protocols typically call for 3 to 6 mg once weekly [4][7].

Weekly dosing aims to intermittently inhibit mTORC1 while avoiding chronic mTORC2 suppression. Sustained mTORC2 inhibition is associated with insulin resistance and immune suppression, effects that continuous daily dosing produces but that pulsed weekly dosing may largely avoid [7]. This distinction drives the growing clinical interest in rapamycin for aging.

The PEARL trial (Aging Cell, 2024) tested 5 mg rapamycin weekly in healthy adults aged 50 to 85. After 8 weeks, participants showed a statistically significant increase in the CD4/CD8 T-cell ratio (P=0.01), suggesting improved immune function rather than suppression [5]. The trial also documented that weekly dosing maintained sirolimus levels well below the transplant therapeutic range.

Dr. Alan Green, a New York physician who has prescribed rapamycin off-label to over 1,000 patients, has stated: "At 5 to 6 mg once a week, we simply do not see the immunosuppression that transplant teams worry about. The pharmacokinetics are entirely different."

Nevada prescribers following off-label longevity protocols will typically start at 3 mg weekly, then titrate to 5 or 6 mg after 4 to 6 weeks if labs remain stable. Some protocols include a 2-week drug holiday every 8 to 12 weeks, though no randomized trial has validated this cycling approach.

How 503A Compounding Pharmacies Work in Nevada

Nevada's Board of Pharmacy licenses 503A compounding pharmacies under NAC 639.645, allowing them to prepare patient-specific prescriptions for sirolimus [8]. This is relevant because compounded rapamycin often costs 40% to 60% less than brand-name Rapamune.

A 503A pharmacy compounds medications based on individual prescriptions. Unlike 503B outsourcing facilities (which produce bulk quantities without patient-specific prescriptions), 503A pharmacies require a valid prescription naming a specific patient before compounding. Nevada allows both in-state 503A pharmacies and out-of-state 503A pharmacies to ship compounded medications to Nevada residents, provided the out-of-state pharmacy holds a Nevada non-resident pharmacy license [8].

Typical compounded rapamycin options include:

• Oral capsules in 1 mg, 2 mg, 3 mg, 5 mg, and 6 mg strengths
• Topical rapamycin (0.1% to 1% cream) for dermatologic applications such as facial angiofibromas in tuberous sclerosis complex [9]

Pricing from Nevada-accessible 503A pharmacies generally runs $1 to $3 per milligram for compounded oral capsules. A 5 mg weekly dose comes to roughly $20 to $60 per month. Brand Rapamune (1 mg tablets from Pfizer) costs approximately $900 to $1,200 for 30 tablets at retail pharmacy pricing without insurance, making compounding the more practical option for most off-label users.

To fill a compounded rapamycin prescription in Nevada, your prescriber sends the Rx electronically or by phone to the compounding pharmacy. The pharmacy prepares the medication (typically within 3 to 5 business days) and ships it to your Nevada address via cold-chain packaging if required.

Nevada Medicaid, Insurance, and Out-of-Pocket Costs

Nevada Medicaid does not cover rapamycin for off-label longevity use. Coverage exists only for FDA-approved indications: prevention of organ transplant rejection and lymphangioleiomyomatosis (LAM) [4][10].

Private insurers in Nevada (including plans through the Silver State Health Insurance Exchange) follow similar patterns. Most commercial formularies list generic sirolimus as a Tier 3 or Tier 4 specialty drug. Prior authorization is required in nearly all cases, and approval for off-label longevity use is rare.

What prior authorization requires in Nevada:

• A diagnosis code supporting an FDA-approved indication (Z94.0 for kidney transplant, J84.81 for LAM)
• Documentation of previous therapy trials (for transplant: typically calcineurin inhibitor history)
• Prescriber attestation of medical necessity
• Lab results demonstrating appropriate monitoring

For patients paying out of pocket, the cost breakdown looks like this:

| Source | Monthly Cost (5 mg weekly) | |---|---| | Brand Rapamune (retail) | $900 to $1,200 | | Generic sirolimus (retail) | $80 to $200 | | Generic sirolimus (GoodRx/discount) | $40 to $120 | | Compounded rapamycin (503A) | $20 to $60 |

GoodRx and similar discount platforms can reduce generic sirolimus prices at Nevada chain pharmacies (CVS, Walgreens, Walmart) to $40 to $120 per month for a 4 mg weekly supply dispensed as 1 mg tablets [11].

Finding a Rapamycin Prescriber in Nevada

Three pathways exist for Nevada residents seeking a rapamycin prescription.

Telehealth longevity clinics. Several national platforms operate in Nevada, staffed by physicians experienced with mTOR inhibitor protocols. These clinics typically charge $150 to $350 for an initial consultation and $75 to $150 for follow-up visits every 3 to 6 months. The consultation includes lab review, dosing recommendations, and prescription management.

In-person anti-aging or functional medicine physicians. Las Vegas and Reno both have functional medicine practices that prescribe rapamycin off-label. The American Academy of Anti-Aging Medicine (A4M) maintains a provider directory searchable by state [12]. Henderson, Summerlin, and the Reno-Sparks metro area have the highest concentration of these practitioners.

Academic medical centers. The Kirk Kerkorian School of Medicine at UNLV and Renown Health in Reno employ transplant-affiliated physicians familiar with sirolimus. These providers more commonly prescribe for on-label indications, but some will consider off-label use with appropriate informed consent documentation.

Whichever pathway you choose, verify that your prescriber:

1. Holds an active Nevada medical license (searchable via the Nevada State Board of Medical Examiners at medboard.nv.gov)
2. Orders and reviews baseline labs before prescribing
3. Schedules follow-up monitoring every 3 to 6 months
4. Provides written informed consent for off-label use

Transferring a Rapamycin Prescription to Nevada

If you already have a rapamycin prescription from another state, Nevada pharmacies can accept a prescription transfer under NRS 639.2358. The process is straightforward.

Your current pharmacy contacts the Nevada pharmacy directly (by phone or electronic transfer), and the Nevada pharmacy receives the remaining refills. No new prescription from a Nevada-licensed provider is required for the transfer itself, though your out-of-state prescriber must be willing to authorize refills dispensed in Nevada [8].

One caveat: if your prescription is from a 503A compounding pharmacy, the transfer process differs. Compounded prescriptions are patient-specific and pharmacy-specific. You will need your prescriber to issue a new prescription to the Nevada-based (or Nevada-licensed) compounding pharmacy. The original compounding pharmacy cannot transfer a compounded Rx the way a retail pharmacy transfers a manufactured drug.

For patients relocating to Nevada, establishing care with a Nevada-licensed telehealth or in-person provider ensures uninterrupted access. Most longevity-focused telehealth platforms can onboard a new patient and issue a Nevada prescription within 7 to 10 business days, assuming recent labs (within 90 days) are available for review.

Monitoring and Safety Considerations for Nevada Patients

Ongoing monitoring is non-negotiable. The FDA label for sirolimus lists over 30 potential adverse effects, though most occur at daily transplant doses rather than weekly longevity protocols [4].

At weekly doses of 3 to 6 mg, the most commonly reported side effects include:

• Mouth sores (aphthous ulcers). Reported in 10% to 20% of off-label users. Typically mild and self-limiting. Some clinicians recommend prophylactic dexamethasone oral rinse [13].
• Lipid elevation. The PEARL trial found mean LDL increases of 8% to 15% at 5 mg weekly [5]. Patients already on statin therapy should have lipids rechecked 6 to 8 weeks after starting rapamycin.
• Acne-like skin eruptions. Occur in approximately 5% to 10% of weekly users, typically resolving within 4 to 6 weeks.

Lab monitoring should occur at 6 weeks, 3 months, and every 6 months thereafter. Repeat the baseline panel (CBC, CMP, fasting lipids, fasting glucose). Add a sirolimus level if clinically indicated. Any new-onset significant thrombocytopenia (platelets <100,000/μL) or neutropenia (ANC <1,500/μL) warrants dose reduction or discontinuation [4].

Nevada patients using telehealth can complete follow-up labs at any LabCorp or Quest location in the state. Results are transmitted electronically to your prescriber, who reviews them and adjusts your protocol as needed during a scheduled video follow-up.

The Geroscience Network's 2024 consensus statement recommends that any physician prescribing rapamycin off-label for aging should document informed consent, monitor metabolic parameters quarterly for the first year, and discontinue therapy if grade 3 or higher adverse events occur [14].

Patients over age 65 or those with a baseline HbA1c above 5.7% should receive glucose monitoring every 8 to 12 weeks during the first 6 months of rapamycin therapy, per the American Diabetes Association's screening guidelines for drug-induced hyperglycemia [15].